What is the recommended systematic treatment approach for community‑acquired pneumonia?

Treatment of Community-Acquired Pneumonia: Systematic Approach for Exam Writing

Outpatient Management (Mild CAP)

Previously Healthy Adults Without Comorbidities

• Amoxicillin 1 g orally three times daily for 5–7 days is the first-line therapy, providing coverage against 90–95% of Streptococcus pneumoniae isolates including many penicillin-resistant strains 1, 2.
• Doxycycline 100 mg orally twice daily for 5–7 days serves as an acceptable alternative when amoxicillin is contraindicated 1, 2.
• Macrolides (azithromycin or clarithromycin) should only be used when local pneumococcal macrolide resistance is documented <25%; in most U.S. regions resistance is 20–30%, making macrolide monotherapy unsafe 1, 2.

Adults With Comorbidities (COPD, Diabetes, Heart/Liver/Renal Disease)

• Combination therapy is mandatory: amoxicillin-clavulanate 875/125 mg orally twice daily plus azithromycin (500 mg day 1, then 250 mg daily for 5–7 days) 1, 2.
• Alternative: respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) for patients with β-lactam allergy, though fluoroquinolones should be reserved due to FDA safety warnings 1, 2.

---

Inpatient Management (Moderate CAP, Non-ICU)

Standard Empiric Regimen

• Ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg IV or orally daily is the preferred regimen, providing coverage for typical pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella) 3, 1, 2.
• Alternative β-lactams include cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours, always combined with azithromycin 3, 1.
• Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) is equally effective and preferred for penicillin-allergic patients 3, 1, 2.

Critical Timing

• Administer the first antibiotic dose in the emergency department immediately upon diagnosis; delays beyond 8 hours increase 30-day mortality by 20–30% 1, 2.
• Obtain blood cultures and sputum Gram stain/culture before the first antibiotic dose to enable pathogen-directed therapy 3, 1, 2.

Transition to Oral Therapy

• Switch from IV to oral antibiotics when the patient is hemodynamically stable (systolic BP ≥90 mmHg, HR ≤100 bpm), clinically improving, afebrile for 48–72 hours, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% on room air, and able to take oral medication—typically by hospital day 2–3 1, 2.
• Oral step-down options: amoxicillin 1 g three times daily plus azithromycin 500 mg daily 1, 2.

---

ICU Management (Severe CAP)

Mandatory Combination Therapy

• Combination therapy is required for all ICU patients; β-lactam monotherapy is associated with higher mortality 3, 1, 2.
• Ceftriaxone 2 g IV once daily plus azithromycin 500 mg IV daily is the preferred regimen 3, 1, 2.
• Alternative: ceftriaxone 2 g IV daily plus a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily) 3, 1.

ICU Admission Criteria

• One major criterion (septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation) or ≥3 minor criteria (confusion, respiratory rate ≥30/min, systolic BP <90 mmHg, multilobar infiltrates, PaO₂/FiO₂ <250) 3, 1.

---

Special Pathogen Coverage (Risk-Based)

Pseudomonas aeruginosa Coverage

• Add antipseudomonal therapy only when risk factors are present: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization with IV antibiotics within 90 days, or prior respiratory isolation of P. aeruginosa 3, 1.
• Regimen: piperacillin-tazobactam 4.5 g IV every 6 hours plus ciprofloxacin 400 mg IV every 8 hours (or levofloxacin 750 mg IV daily) plus an aminoglycoside (gentamicin 5–7 mg/kg IV daily) for dual antipseudomonal coverage 3, 1.

MRSA Coverage

• Add MRSA therapy only when risk factors are present: prior MRSA infection/colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging 3, 1.
• Regimen: vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base regimen 3, 1.

---

Duration of Therapy

Standard Duration

• Minimum of 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability 1, 2, 4, 5.
• Typical duration for uncomplicated CAP is 5–7 days 1, 2, 4, 5.
• Extended duration (14–21 days) is required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli 1, 2.

New Evidence on Shorter Courses

• Recent trials demonstrate that 3-day treatment is effective for non-severe or moderate CAP stabilized at day 3, and 5-day treatment when stability is achieved by day 5 5, 6.
• Short-course treatment (≤6 days) has equivalent clinical cure rates with fewer adverse events compared to longer durations (≥7 days) 2, 5.

---

Critical Pitfalls to Avoid

Antibiotic Selection Errors

• Never use macrolide monotherapy in hospitalized patients; it fails to cover typical pathogens like S. pneumoniae and leads to treatment failure 1, 2.
• Avoid macrolide monotherapy in outpatients when local pneumococcal macrolide resistance exceeds 25% (most U.S. regions) 1, 2.
• Do not use β-lactam monotherapy in ICU patients; combination therapy reduces mortality 3, 1, 2.

Unnecessary Broad-Spectrum Use

• Do not add antipseudomonal agents (piperacillin-tazobactam, cefepime) or MRSA coverage (vancomycin, linezolid) routinely; restrict to patients with documented risk factors to prevent resistance 3, 1, 2.
• Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection) and rising resistance 1, 2.

Duration Errors

• Do not extend therapy beyond 7–8 days in responding patients without specific indications; longer courses increase antimicrobial resistance risk without improving outcomes 1, 2.

---

Monitoring and Follow-Up

Inpatient Monitoring

• Monitor temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily 1, 2.
• If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to assess for complications (pleural effusion, empyema, resistant organisms) 1, 2.

Outpatient Follow-Up

• Clinical review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and adherence 1, 2.
• Routine follow-up at 6 weeks for all patients; chest radiograph only if symptoms persist, physical signs remain, or high risk for underlying malignancy (smokers >50 years) 1, 2.

---

Summary Algorithm

1. Assess Severity:

• Outpatient (PSI I–III, CURB-65 0–1) → oral antibiotics
• Inpatient non-ICU (PSI IV, CURB-65 ≥2) → IV antibiotics
• ICU (major criterion or ≥3 minor criteria) → combination IV therapy

2. Select Empiric Regimen:

• Outpatient healthy: amoxicillin 1 g TID
• Outpatient with comorbidities: amoxicillin-clavulanate + azithromycin
• Inpatient non-ICU: ceftriaxone 1–2 g IV daily + azithromycin 500 mg daily
• ICU: ceftriaxone 2 g IV daily + azithromycin 500 mg IV daily

3. Add Special Coverage (if risk factors present):

• Pseudomonas: piperacillin-tazobactam + ciprofloxacin + aminoglycoside
• MRSA: vancomycin or linezolid

4. Duration:

• Minimum 5 days, until afebrile 48–72 hours with ≤1 instability sign
• Typical 5–7 days for uncomplicated CAP
• Extended 14–21 days for Legionella, S. aureus, or Gram-negative enteric bacilli

5. Transition to Oral:

• When clinically stable (typically day 2–3)

6. Follow-Up:

• Outpatient: 48 hours
• All patients: 6 weeks